Maintenance Therapy for Erosive Esophagitis in Children After Healing by Omeprazole: Is It Advisable?

Boccia, Gabriella; Manguso, Francesco; Miele, Erasmo; Buonavolontà, Roberta; Staiano, Annamaria
June 2007
American Journal of Gastroenterology;Jun2007, Vol. 102 Issue 6, p1291
Academic Journal
OBJECTIVES: To evaluate the efficacy of acid-suppressive maintenance therapy for gastroesophageal reflux disease (GERD) in children, after the healing of reflux esophagitis. METHODS: Forty-eight children (median age 105 months, range 32–170) with erosive reflux esophagitis were initially treated with omeprazole 1.4 mg/kg/day for 3 months. Patients in endoscopic remission were assigned in a randomized, blinded manner by means of a computer-generated list to three groups of 6-month maintenance treatment: group A (omeprazole at half the starting dose, once daily before breakfast), group B (ranitidine 10 mg/kg/day, divided in two doses), and group C (no treatment). Endoscopic, histological, and symptomatic scores were evaluated at: T0, enrollment; T1, assessment for remission at 3 months after enrollment (healing phase); T2, assessment for effective maintenance at 12 months after T0 (3 months after the completion of the maintenance phase). Relapse was defined as the recurrence of macroscopic esophageal lesions. After the completion of the maintenance phase, patients without macroscopic esophagitis relapse were followed up for GERD symptoms for a further period of 30 months. RESULTS: Of 48 initially treated patients, 46 (94%) healed and entered the maintenance study. For all patients, in comparison to T0, the histological, endoscopic, and symptomatic scores were significantly reduced both at T1 and T2 ( P < 0.0001, for each). No significant difference was found in these three scores, comparing group A, B, and C at T1 and T2. A relapse occurred in one patient only, who presented with macroscopic esophageal lesions at T2. Three months after the completion of the maintenance phase, 12 (26%) patients complained of symptoms sufficiently mild to discontinue GERD therapy, excluding the patient who showed macroscopic esophagitis relapse. Three of 44 (6.8%) patients reported very mild GERD symptoms within a period of 30 months after maintenance discontinuation. CONCLUSIONS: Our pediatric population showed a low rate of erosive esophagitis relapse and GERD symptom recurrence long term after healing with omeprazole, irrespective of the maintenance therapy.


Related Articles

  • Omeprazole maintenance therapy for GERD. Parks, Susan Mockus // Journal of Family Practice;Oct97, Vol. 45 Issue 4, p292 

    The article discusses research being done on the effectiveness of omeprazole maintenance therapy on gastroesophageal reflux disease (GERD). It references a study by T. L. Venables, R. D. Newland, A. C. Patel, J. Hole, M. B. Copeman and M. L. Turbitt published in the 1997 issue of "Scandinavian...

  • Hemolytic Anemia Associated with the Use of Omeprazole. Marks, David R.; Joy, James V; Bonheim, Nelson A. // American Journal of Gastroenterology;Feb1991, Vol. 86 Issue 2, p217 

    Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell. It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome. Although clinical experience with...

  • Effect of a Combination of Omeprazole Plus Sustained Release Baclofen Versus Omeprazole Alone on Symptoms of Patients with Gastroesophageal Reflux Disease (GERD). Abbasinazari, Mohammad; Panahi, Yunes; Alireza Mortazavi, Seyed; Fahimi, Fanak; Valizadegan, Ghasem; Mohtashami, Reza; Amin Pourhoseingholi, Mohammad; Shirvani Bakhtiari, Kambiz // Iranian Journal of Pharmaceutical Research;2014, Vol. 13 Issue 4, p1221 

    Previous studies have reported the efficacy of baclofen in the treatment of Gastroesophageal Reflux Diseases (GERD). The objective of present study is to evaluate the effect of co-administration of omeprazole 20 mg/d plus sustained Release baclofen (SR baclofen) vs. omeprazole 20 mg/d plus...

  • Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Taghavi, S. A.; Ghasedi, M.; Saberi-Firoozi, M.; Alizadeh-Naeeni, M.; Bagheri-Lankarani, K.; Kaviani, M. J.; Hamidpour, L. // Gut;Aug2005, Vol. 54 Issue 8, p1067 

    Background: Twenty four hour oesophageal pH monitoring is frequently used to quantify the association between a patient's symptom and gastro-oesophageal reflux. Three indices (symptom association probability (SAP), symptom index (SI), and symptom sensitivity index (SSI)) are used to quantify and...

  • Natural Course of Gastroesophageal Reflux Disease: 17-22 Year Follow-Up of 60 Patients. Isolauri, Jouko; Luostarinen, Markku; Isolauri, Erika; Reinikainen, Pekka; Viljakka, Mikko; Keyriläinen, Olavi // American Journal of Gastroenterology;Jan1997, Vol. 92 Issue 1, p37 

    Objective: To elucidate the long-term course of conservatively managed gastroesophageal reflux disease without H2-antagonists or omeprazole. Methods: Design: Clinical trial, uncontrolled. Setting: Gastroenterological outpatient department of a teaching hospital. Patients: Sixty of 87 patients...

  • Effect of Omeprazole and High Doses of Ranitidine on Gastric Acidity and Gastroesophageal Reflux in Patients with Moderate-Severe Esophagitis. Fiorucci, Stefano; Santucci, Luca; Morelli, Antonio // American Journal of Gastroenterology;Nov1990, Vol. 85 Issue 11, p1458 

    Thirty to fifty percent of patients with reflux esophagitis fail to heal after treatment with conventional doses of 112-receptor antagonists, whereas omeprazole administration induces more than 90% healing. To investigate the effect of omeprazole and higher-than-presently-recommended doses of...

  • OMEPRAZOLE OR RANITIDINE FOR INTERMITTENT TREATMENT OF GERD? Salzberg, Sarah A.; Newton, Warren P. // Journal of Family Practice;May99, Vol. 48 Issue 5, p332 

    The article presents information on a study that examines the suitability of using omeprazole or ranitidine for the intermittent treatment of gastroesophageal reflux disease (GERD). GERD is a common diagnosis in primary care, but optimal management is not well defined. Continuous treatment with...

  • Gastroesophageal Reflux in Children. Shepherd, R. W.; Wren, J.; Evans, S.; Lander, M.; Ong, T. H. // Clinical Pediatrics;Feb1987, Vol. 26 Issue 2, p55 

    A clinical profile and the course and outcome with therapy of 126 infants and children with gastroesophageal reflux (CER), diagnosed at a median age of 2.5 months and followed for 1.5 to 3.5 yam is presented. Features included repeated regurgitation or rumination (99%), signs suggesting...

  • Sucralfate Maintenance Therapy in Reflux Esophagitis. Tytgat, G. N. J.; Koelz, H.-R.; Vosmaer, G. D. C. // American Journal of Gastroenterology;Aug1995, Vol. 90 Issue 8, p1233 

    Objective: to prove in a double-blind placebo-controlled multinational trial the effects of sucralfate suspension 2 g BID and placebo in the prevention of recurrent reflux esophagitis. Methods: One hundred and eighty-four patients from 16 centers with reflux esophagitis Savary grade 1 and 2 were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics